Inmune Bio, Inc. Files 8-K Report
Ticker: INMB · Form: 8-K · Filed: Oct 28, 2025 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, biotech
Related Tickers: INMB
TL;DR
INMB filed a routine 8-K, no major news yet.
AI Summary
On October 23, 2025, Inmune Bio, Inc. filed an 8-K report. The filing indicates that the company is a biotechnology firm incorporated in Nevada, with its principal executive offices located in Boca Raton, Florida. The report does not detail specific events or financial transactions but serves as a current report filed under the Securities Exchange Act of 1934.
Why It Matters
This filing is a standard procedural update for Inmune Bio, Inc., indicating ongoing compliance with SEC reporting requirements.
Risk Assessment
Risk Level: low — This is a routine filing with no new material information disclosed.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- Boca Raton, Florida (location) — Principal Executive Offices
- October 23, 2025 (date) — Date of earliest event reported
FAQ
What is the primary business of Inmune Bio, Inc.?
Inmune Bio, Inc. is a biotechnology company specializing in biological products, excluding diagnostic substances, as indicated by its SIC code 2836.
When was this 8-K report filed?
The report was filed on October 28, 2025, with the earliest event reported being October 23, 2025.
Where is Inmune Bio, Inc. headquartered?
The company's principal executive offices are located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What is the company's state of incorporation?
Inmune Bio, Inc. is incorporated in Nevada.
What is the SEC file number for Inmune Bio, Inc.?
The SEC file number for Inmune Bio, Inc. is 001-38793.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-10-28 16:01:37
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0262255-8k_inmune.htm (8-K) — 23KB
- ea026225501ex99-1_inmune.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-103068.txt ( ) — 204KB
- inmb-20251023.xsd (EX-101.SCH) — 3KB
- inmb-20251023_lab.xml (EX-101.LAB) — 33KB
- inmb-20251023_pre.xml (EX-101.PRE) — 22KB
- ea0262255-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On October 23, 2025, INmune Bio Inc. issued a press release announcing that it will host a conference call on Thursday, October 30, 2025, at 4:30 p.m., Eastern Time to discuss results for its third quarter ended September 30, 2025, and to provide a corporate update. A copy of the press release is attached herewith as Exhibit 99.1. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release, dated October 23, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: October 28, 2025 By: /s/ David Moss David Moss Chief Executive Officer 2